Skip to Content

Join the 'Rifapentine' group to help and get support from people like you.

Rifapentine News

Global Efforts to Combat TB Epidemic Falling Short

Posted 13 Oct 2016 by Drugs.com

THURSDAY, Oct. 13, 2016 – Countries around the world need to work harder to combat tuberculosis infections and deaths, a new World Health Organization report says. Nations across the globe have pledged to reduce tuberculosis (TB) infections by 80 percent and TB deaths by 90 percent by 2030, but they must work faster if they want to meet these goals, according to the WHO. "We face an uphill battle to reach the global targets for tuberculosis," WHO Director General Dr. Margaret Chan said in an organization news release. "There must be a massive scale-up of efforts, or countries will continue to run behind this deadly epidemic and these ambitious goals will be missed." Tuberculosis is a disease that mainly affects the lungs. The bacteria that cause TB are primarily spread from person to person through tiny droplets from coughs and sneezes. The global response to the TB epidemic did manage ... Read more

Related support groups: Tuberculosis, Rifampin, Tuberculosis - Latent, Ethambutol, Tuberculosis - Active, Pulmonary Tuberculosis, Tuberculosis - Prophylaxis, Pyrazinamide, Diagnosis and Investigation, Tuberculosis - Extrapulmonary, Rifamate, Isoniazid/Rifampin, Rifabutin, Tuberculosis - Resistant, Mycobutin, Rifadin, Tuberculosis - HIV Negative, Tuberculosis - HIV Status Unknown, Tuberculous Meningitis, Myambutol

Tuberculosis Decline in U.S. Has Stalled, CDC Reports

Posted 24 Mar 2016 by Drugs.com

THURSDAY, March 24, 2016 – Two decades of progress toward eliminating tuberculosis in the United States has stalled, with incidence of the lung disease holding steady from 2013 to 2015, a federal government report shows. "Resuming progress toward TB elimination in the United States will require intensification of efforts both in the U.S. and globally," said researchers from the U.S. Centers for Disease Control and Prevention's National Tuberculosis Surveillance System. If not treated, TB can be fatal. The bacterial infection is spread through the air, when someone infected coughs, sneezes or speaks. However, it is not easily transmitted – you must be in close contact with someone who has TB for a long period of time, according to the American Lung Association. Overall, TB incidence leveled off at about three new cases per 100,000 people each year between 2013 and 2015, according to ... Read more

Related support groups: Xifaxan, Tuberculosis, Rifampin, Rifaximin, Tuberculosis - Latent, Tuberculosis - Active, Pulmonary Tuberculosis, Tuberculosis - Prophylaxis, Tuberculosis - Extrapulmonary, Rifabutin, Isoniazid/Rifampin, Rifamate, Tuberculosis - HIV Negative, Rifater, Mycobutin, Tuberculosis - Resistant, Rifadin, IsonaRif, Priftin, Isoniazid/Pyrazinamide/Rifampin

E-Pillboxes Improve Medication Adherence, Study Finds

Posted 15 Sep 2015 by Drugs.com

TUESDAY, Sept. 15, 2015 – Electronic reminders may help people with tuberculosis take their medication properly, a new study suggests. Tuberculosis (TB) patients are less likely to miss doses when they receive alerts from an electronic pillbox, researchers report in the Sept. 15 issue of PLOS Medicine. Electronic pillboxes use visual, audio and/or vibration cues to signal when it's time to take medication. TB is a bacterial infection that mainly strikes the lungs. The traditional method of ensuring medical adherence in TB patients is to watch people take their medicine, but the study authors said this isn't doable in remote areas such as rural China. "Innovative approaches to enable patients to adhere to TB treatment are needed. Widespread use of medication monitors in national TB control programs can benefit from the development of a low-cost and reliable medication monitor as well as ... Read more

Related support groups: Tuberculosis, Isoniazid, Rifampin, Ethambutol, Tuberculosis - Active, Pulmonary Tuberculosis, Tuberculosis - Prophylaxis, Pyrazinamide, Tuberculosis - Extrapulmonary, Isoniazid/Rifampin, Rifabutin, Rifamate, Mycobutin, Rifater, Myambutol, Rifadin, IsonaRif, Rimactane, Priftin, Rifadin IV

Sanofi Receives FDA Approval of Priftin (rifapentine) for Latent Tuberculosis Infection

Posted 2 Dec 2014 by Drugs.com

Bridgewater, NJ – December 2, 2014 / PR Newswire / — Sanofi announced today that following a priority review, the U.S. Food and Drug Administration has approved Priftin (rifapentine) in combination with isoniazid (INH) for a new indication for the treatment of latent tuberculosis infection (LTBI) in patients two years of age and older at high risk of progression to tuberculosis (TB) disease. Priftin is an antimycobacterial that has been approved since 1998, in combination with one or more antituberculosis drugs, for the treatment of active pulmonary TB caused by Mycobacterium tuberculosis. A person with LTBI is infected with the bacteria that cause TB, but does not feel sick, have symptoms, and cannot spread the bacteria to others. More than 11 million people living in the United States have LTBI, and about five to 10 percent of those – up to more than 1 million people – will develop TB ... Read more

Related support groups: Tuberculosis - Latent, Tuberculosis - Active, Priftin, Rifapentine

CDC Issues New TB Treatment Guidelines

Posted 8 Dec 2011 by Drugs.com

THURSDAY, Dec. 8 – New guidelines on treating so-called "latent" tuberculosis infection in the United States should significantly shorten and simplify the course of the therapy from about 9 months to 3 months, according to the U.S. Centers for Disease Control and Prevention. The new guidelines for public health officials and health care providers – which are based on expert opinion and the results of three clinical trials – are a "game changer" for the treatment of TB in the United States, according to CDC Director Dr. Thomas Frieden. Latent TB infection occurs when a person is infected with TB bacteria but does not yet have symptoms and so cannot transmit the bacteria to others. However, if the bacteria becomes active, the person will develop the disease and can also spread it to others. Certain people, including those with weakened immune systems, are more likely to progress from ... Read more

Related support groups: Tuberculosis, Isoniazid, Tuberculosis - Latent, Nydrazid, Priftin, Rifapentine

New Combo Therapy May Prevent TB, Save Lives in People With HIV

Posted 6 Jul 2011 by Drugs.com

WEDNESDAY, July 6 – Simpler and shorter treatment with antibiotic drugs could help prevent full-blown tuberculosis in millions of people worldwide infected with the bacterium that causes TB, especially those also infected with HIV, researchers report. TB, or tuberculosis, is the leading cause of death among people co-infected with HIV, the virus that causes AIDS. About half a million people with both infections die worldwide every year. The new study by an international team of scientists included 1,148 South African men and women infected with the TB bacterium and HIV, who were followed for up to six years to see whose TB infections stayed dormant. It found that the most streamlined combination treatment – a high dose of 900 milligrams each of the newer antibiotic rifapentine (Priftin) and the traditional anti-TB antibiotic isoniazid once weekly for three months – worked as well or ... Read more

Related support groups: Isoniazid, Tuberculosis - Prophylaxis, Nydrazid, Rifapentine, Priftin

Ask a Question

Further Information

Related Condition Support Groups

Tuberculosis - Latent, Tuberculosis - Active

Related Drug Support Groups

Priftin

Rifapentine Patient Information at Drugs.com